Literature DB >> 24332697

Comparison of the frequencies of myocardial edema determined by cardiac magnetic resonance in diabetic versus nondiabetic patients having percutaneous coronary intervention for ST elevation myocardial infarction.

Mohammad I Zia1, Nilesh R Ghugre2, Idan Roifman2, Bradley H Strauss2, Rhonda Walcarius2, Malaika Mohammed2, John D Sparkes2, Alexander J Dick2, Graham A Wright2, Kim A Connelly3.   

Abstract

The specific mechanisms by which diabetes may affect the myocardial tissue response to ischemia are unclear. Our objective was to prospectively quantify the degree of myocardial edema in diabetics versus nondiabetics with ST elevation myocardial infarction using cardiac magnetic resonance. Fifty-two patients (16 diabetics and 36 nondiabetics) were enrolled after primary percutaneous coronary intervention and underwent cardiac magnetic resonance on a 1.5-T scanner at 48 hours and 6 months. Myocardial edema was quantified using a T2 mapping technique, and infarct size and microvascular obstruction size were assessed by way of a contrast-enhanced T1-weighted inversion recovery gradient-echo sequence. The infarct segment T2 was elevated in diabetics compared with nondiabetics (59.0 ± 8.0 vs 50.8 ± 3.1 ms, p <0.001) at 48 hours. Multivariate analysis demonstrated that diabetes (p <0.001) and symptom-to-balloon time (p = 0.04) were independent predictors of the degree of acute myocardial edema. Infarct size was nonsignificantly higher in the diabetic group at 48 hours (26.9 ± 9.4% vs 20.1 ± 10.1% of myocardium, p = 0.07) and 6 months (17.1 ± 6.3% vs 13.4 ± 6.1% of myocardium, p = 0.09). Microvascular obstruction size was equivalent in both groups, and there was a trend toward lower myocardial salvage index in diabetics (34.2 ± 11.8 vs 49.6 ± 13.4, p = 0.08). In conclusion, diabetes is associated with increased myocardial edema in the acute phase after primary percutaneous coronary intervention. Our results offer insight into the complex processes that characterize myocardial tissue response to injury in diabetic patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24332697     DOI: 10.1016/j.amjcard.2013.10.040

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Ischemic conditioning: the challenge of protecting the diabetic heart.

Authors:  Joseph Wider; Karin Przyklenk
Journal:  Cardiovasc Diagn Ther       Date:  2014-10

2.  Assessment of the longitudinal changes in infarct heterogeneity post myocardial infarction.

Authors:  Idan Roifman; Nilesh R Ghugre; Tasnim Vira; Mohammad I Zia; Anna Zavodni; Mihaela Pop; Kim A Connelly; Graham A Wright
Journal:  BMC Cardiovasc Disord       Date:  2016-10-14       Impact factor: 2.298

Review 3.  Cardiovascular magnetic resonance imaging assessment of outcomes in acute myocardial infarction.

Authors:  Jamal N Khan; Gerry P McCann
Journal:  World J Cardiol       Date:  2017-02-26

4.  Vascular endothelial growth factor promotes atrial arrhythmias by inducing acute intercalated disk remodeling.

Authors:  Louisa Mezache; Heather L Struckman; Amara Greer-Short; Stephen Baine; Sándor Györke; Przemysław B Radwański; Thomas J Hund; Rengasayee Veeraraghavan
Journal:  Sci Rep       Date:  2020-11-24       Impact factor: 4.379

Review 5.  Myocardial oedema: pathophysiological basis and implications for the failing heart.

Authors:  Francisco Vasques-Nóvoa; António Angélico-Gonçalves; José M G Alvarenga; João Nobrega; Rui J Cerqueira; Jennifer Mancio; Adelino F Leite-Moreira; Roberto Roncon-Albuquerque
Journal:  ESC Heart Fail       Date:  2022-02-11

6.  Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction.

Authors:  Lara S F Konijnenberg; Peter Damman; Dirk J Duncker; Robert A Kloner; Robin Nijveldt; Robert-Jan M van Geuns; Colin Berry; Niels P Riksen; Javier Escaned; Niels van Royen
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.